(Q40206658)

18 September 2017

title

Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease (English)

1 reference

inflammatory bowel diseases

18 September 2017

main subject

0 references

0 references

2

Gary R Lichtenstein

1 reference

18 September 2017

Mark T Osterman

1

1 reference

18 September 2017

publication date

1 June 2007

1 reference

Current treatment options in gastroenterology

18 September 2017

published in

1 reference

18 September 2017

volume

10

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

195-207

1 reference

https://scigraph.springernature.com/pub.10.1007/s11938-007-0013-3

18 September 2017

exact match

0 references

cites work

Listeria meningitis after treatment with infliximab

1 reference

12 December 2020

Tumor necrosis factor: biology and therapeutic inhibitors

1 reference

12 December 2020

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

12 December 2020

Role of cytokines in the pathogenesis of inflammatory bowel disease

1 reference

12 December 2020

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

12 December 2020

Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

12 December 2020

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

12 December 2020

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

12 December 2020

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

12 December 2020

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

1 reference

12 December 2020

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

12 December 2020

Reactivation of histoplasmosis after treatment with infliximab

1 reference

12 December 2020

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

12 December 2020

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

12 December 2020

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

1 reference

12 December 2020

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

12 December 2020

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

1 reference

12 December 2020

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.

1 reference

12 December 2020

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

1 reference

12 December 2020

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

12 December 2020

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

1 reference

12 December 2020

Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report

1 reference

12 December 2020

Does administration of infliximab increase susceptibility to listeriosis?

1 reference

12 December 2020

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

1 reference

12 December 2020

Infliximab in the surgical management of complex fistulating anal Crohn's disease.

1 reference

12 December 2020

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

12 December 2020

Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement.

1 reference

12 December 2020

10.1007/S11938-007-0013-3

Identifiers

DOI

1 reference

Dimensions Publication ID

18 September 2017

1023506286

0 references

Fatcat ID

release_d7c26dcjrrelbmi26bczvezbd4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d7c26dcjrrelbmi26bczvezbd4

24 November 2022

mapped directly with Wikidata item

1 reference